PFE - ViiV Healthcare doublet HIV therapy shows long-term benefit

Five-year data from the Phase 2b LATTE-2 study and 12-month data from the Phase 2b POLAR rollover study showed sustained benefits from ViiV Healthcare's doublet injectable HIV regimen of cabotegravir and rilpivirine, potentially reducing the number of treatment days to six from 365 while maintaining viral suppression. The results were presented at the IDWeek conference.In LATTE-2, 88% (n=101/115) of participants receiving the two-month regimen and 74% (n=85/115) receiving the monthly regimen remained virally suppressed, although both lagged the proportion [93% (n=41/44)] of patients in the oral three-drug therapy comparator arm who remained virally suppressed at year five. 19% (n=44/230) of the patients receiving the injectable regimens were not virally suppressed at year five, but 40 had no virologic data available for review since they left the study prior to the time point.In POLAR, 97 virologically suppressed HIV-positive patients, including participants who rolled over from LATTE after completing six years of

For further details see:

ViiV Healthcare doublet HIV therapy shows long-term benefit